Novo Nordisk A/S launches oral Wegovy in the U.S. with aggressive pricing as China patent expiry looms. Click for this ...
The U.S. Food and Drug Administration's approval of an oral version of Novo Nordisk's weight-loss drug Wegovy could ...
CHONGQING, CHINA - SEPTEMBER 10: In this photo illustration, the logo of Novo Nordisk is displayed on a smartphone screen on September 10, 2025 in Chongqing, China. The maker of Wegovy and Ozempic, ...
Novo Nordisk’s oral Wegovy gets FDA approval, but rising costs and competition threaten profits. Learn why analysts rate NVO ...
Novo Nordisk's latest quarterly update disappointed investors -- again. But the company has a lot going on behind the scenes that affects its outlook. Between a strong pipeline and a reasonable ...
Novo Nordisk announced a 57% reduction in the risk of heart attacks, strokes, and death by any cause for patients taking Wegovy versus Eli Lilly's Zepbound. The Steer study results aren't nearly as ...
Semaglutide failed to demonstrate slowed Alzheimer’s progression in EVOKE/EVOKE+ preliminary results, though some biomarkers improved. Stock plunged intraday, then partly recovered; shares are down ...
When Novo Nordisk launched Wegovy, its pioneering weight-loss jab, in America in June 2021, it felt like it was “running into a dark tunnel”, recalls Maziar Mike Doustdar, who took over as the Danish ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback